Katrine Bosley is the CEO of Editas Medicine and the former CEO of Avila Therapeutics, a company that championed the discovery and development of targeted covalent drugs. Avila established alliances with Sanofi, Clovis Oncology, and the Leukemia & Lymphoma Society and advanced two programs into clinical development, one independently and one with partner Clovis, prior to its acquisition by Celgene in early 2012 ($350 million upfront + $575 million contingent on milestones).
Prior to her leadership at Avila, Katrine was VP, Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics called Adnectins. Adnexus was acquired by Bristol-Myers Squibb in 2007 (>$500 million). Katrine joined Adnexus from Biogen Idec where she led multiple business development transactions, including the in-licensing of Tysabri® (natalizumab). Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners and was in regulatory affairs at Alkermes. Through her career, Katrine has worked with products from discovery through commercialization.
Katrine graduated from Cornell University with a B.A. in biology as a College Scholar and completed the Program for Management Development at Harvard Business School.
That is a sobering headline to write.
Twenty-five years ago at this time of year, I was graduating from college with no job, a pretty choppy economy, a bunch of student... Read more »
As Warren Buffett once pointed out, companies get the investors they deserve.
Observations by the oracle-from-Omaha are hard to dispute, but how does that translate into practice if you’re a biotech... Read more »
Except here... Read more »
It used to be that every young biotech company’s goal was to “go long,” to become a FIPCO (fully integrated pharmaceutical company…remember when that phrase was in vogue?), selling its own... Read more »
June 13, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.